These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36226470)

  • 81. Locally Advanced Cutaneous Squamous Cell Carcinoma Treated With Immunotherapy in a Dermatology Department.
    Navarro Navarro I; Villegas Romero I; Jiménez Gallo D; Linares Barrios M
    Actas Dermosifiliogr; 2023 Mar; 114(3):285-287. PubMed ID: 36370835
    [No Abstract]   [Full Text] [Related]  

  • 82. Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab.
    Escobar GF; Granel-Brocard F; Schmutz JL; Cervantes P; Ben Mahmoud S; Bursztejn AC
    Dermatol Ther; 2020 Nov; 33(6):e13951. PubMed ID: 32614130
    [No Abstract]   [Full Text] [Related]  

  • 83. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
    Bornstein G; Ben-Zvi I; Furie N; Grossman C
    Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report.
    Geidel G; Rünger A; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():49-52. PubMed ID: 34855252
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Cutaneous squamous cell carcinoma].
    Leiter U; Gutzmer R; Alter M; Ulrich C; Meiwes A; Heppt MV; Steeb T; Berking C; Lonsdorf AS; Sachse MM; Garbe C; Hillen U
    Hautarzt; 2020 Aug; 71(8):597-606. PubMed ID: 32583034
    [TBL] [Abstract][Full Text] [Related]  

  • 86. First Drug Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma.
    Aschenbrenner DS
    Am J Nurs; 2019 Jan; 119(1):27. PubMed ID: 30589700
    [No Abstract]   [Full Text] [Related]  

  • 87. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma.
    Tsibris H; Lian C; Ho A
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999581
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
    Borradori L; Sutton B; Shayesteh P; Daniels GA
    Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
    [No Abstract]   [Full Text] [Related]  

  • 89. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.
    Pezeshki S; Hemmati S; Rezaei N
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):819-822. PubMed ID: 32852235
    [No Abstract]   [Full Text] [Related]  

  • 90. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
    Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Posterior Uveitis Associated with Cemiplimab.
    Dow ER; Hou K; Ransome S; Abbassi S; Tsui E
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1211-1213. PubMed ID: 33793370
    [TBL] [Abstract][Full Text] [Related]  

  • 93. New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis.
    Nozaki Y
    Front Immunol; 2021; 12():631055. PubMed ID: 33868250
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Medical treatment of advanced cutaneous squamous-cell carcinoma.
    Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
    [TBL] [Abstract][Full Text] [Related]  

  • 95. What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.
    Coskun Benlidayi I
    Int J Rheum Dis; 2021 May; 24(5):724-727. PubMed ID: 33835676
    [No Abstract]   [Full Text] [Related]  

  • 96. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.
    Galer CE; Corey CL; Wang Z; Younes MN; Gomez-Rivera F; Jasser SA; Ludwig DL; El-Naggar AK; Weber RS; Myers JN
    Head Neck; 2011 Feb; 33(2):189-98. PubMed ID: 20848439
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Landmark Series: Non-melanoma Skin Cancers.
    Lee AY; Berman RS
    Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.
    De Giorgi V; Trane L; Savarese I; Silvestri F; Venturi F; Zuccaro B; Scarfì F
    Clin Exp Dermatol; 2021 Dec; 46(8):1612-1614. PubMed ID: 34157152
    [No Abstract]   [Full Text] [Related]  

  • 100. Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma.
    Frederick JW; Sweeny L; Hartman Y; Zhou T; Rosenthal EL
    Head Neck; 2016 Feb; 38(2):247-52. PubMed ID: 25270595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.